They previously discovered a novel interaction between the BMP type Ia receptor (BMPRIa) and an interacting protein called casein kinase II (CK2).
The Nohe lab has extensively studied this protein and its signaling pathway. While BMP2 may not be an effective or ideal treatment for OP, its signaling pathway is still of interest since it controls both osteoblasts and osteoclasts. Recently, many studies have showed a lack of BMP2 response in OP patients.
☐ Bone morphogenetic protein 2 (BMP2) is a potent growth factor that is known to activate both osteoblasts and osteoclasts. Therefore, there is a need to develop new therapeutics that target both osteoblasts and osteoclasts to treat this debilitating bone disease. Current therapeutics treating OP have a laundry list of negative side effects, and a majority can be taken only for a limited number of years, with drug holidays interspersed throughout their use. The most common bone disease in humans is osteoporosis (OP), which is characterized by low bone mineral density. However, there are many different bone diseases in humans where bone becomes unhealthy or the critical balance between osteoblasts and osteoclasts may become disrupted. Two major cell types found within bone that are responsible for its maintenance are osteoblasts (bone building cells) and osteoclasts (bone resorbing cells).
Department: University of Delaware, Department of Biological SciencesĪbstract: Bone is an extremely important organ as it provides structure, protects other internal organs, anchors muscles to assist in locomotion, and supports mineral homeostasis.
0 kommentar(er)
